Objectives: The aim of this study was to identify the status of the blood supply in China during 2012-2014.
in China; the most recent was a series of surveys beginning in 2009. The survey captured data regarding blood collection, processing, supply and other blood centre-related activities in China. Here, we report the survey results of the national blood supply in China during 2012-2014.
MATERIALS AND METHODS

Survey instrument
A 14-page survey instrument consisting of 13 sections including 81 questions was employed for this survey. The sections in the survey were as follows: information regarding the institution; blood collection vehicle (house); blood collection; blood supply; publicity of blood donation and blood donor recruitment; blood donor information management; blood use policy, blood donor testing, blood product quality control, blood donor management, blood donation of the staff at the blood centre, strategy to manage blood shortages; and government support for blood donation.
Survey sample and response rates
In China, there are 354 blood centres, including 32 provincial blood centres and 322 regional blood centres located throughout the country. Whole blood or blood components are collected by blood centres only. All blood centres were included in this survey. After 5 June 2015, representatives from all the blood centres visited the CSBT site (www.csbt.org.cn) and downloaded the survey packets, which could be submitted via e-mail or regular mail. Up to 30 August 2015, only four regional blood centres did not submit the survey, thereby yielding a response rate of 98·9% (350/354).
Validation of the survey data
All of the survey data were obtained from official statistics, and to ensure the accuracy of the survey data, 30% of the questionnaires were randomly selected by CSBT staff and confirmed by telephone interviews. All 350 questionnaires were confirmed to be valid. 
The definition of the terms
A 200 mL donation volume of whole blood (WB) defines one unit. One unit of blood components [except for apheresis platelets (PLTs) and plasma] is derived from one unit of WB. A 100 mL volume of plasma defines one unit.
Statistical analysis
Statistical analyses were performed using Microsoft Excel 2013.
RESULTS
The rates and the amount of blood supply of WB and RBCs during 2012-2014 in China are summarized in Table 1 The rates and amount of supply of PLT products during 2012-2014 in China are summarized in Table 2 . The rate and the amount of PLT supply increased gradually from 2012 to 2014. The percentages and amount of apheresis PLTs in the total PLT supply increased gradually during the period of 2012-2014, whereas the percentages and amount of WB-derived PLT concentrates decreased.
The rates and amount of plasma supply during 2012-2014 in China are summarized in Table 3 . The amount of plasma supply increased gradually from 2012 to 2014, while the rate of plasma supplied decreased from 2012 to 2013, and increased from 2013 to 2014. The percentages and amount of fresh-frozen plasma and methylene blue-treated and removed frozen plasma in the total plasma supply were elevated during the period of 2012-2014, whereas the percentages and amount of frozen plasma were decreased.
The rates and amount of blood supply of cryoprecipitate in China during 2012-2014 are summarized in Table 4 . The rate and the amount of cryoprecipitate supply increased gradually from 2012 to 2014.
When the blood supply was analysed according to the geographic regional population in China (demographic data obtained from the National Bureau of Statistics of China, http:// data.stats.gov.cn/index.htm), large differences between regions were evident (Fig. 1) . For example, in 2014, the supply rates (units per 1000 population) of WB, red cells and PLTs in North China were the highest. The rate of cryoprecipitate supply in South China was the highest. The supply rate of plasma in East China was the highest. The rates of WB, red cell and PLTs supply in the Southwest were the lowest. The supply rate of plasma in Central China was the lowest. The rate of cryoprecipitate supply in North China was the lowest.
DISCUSSION
Blood transfusion plays an important role in saving patients' lives. Ensuring a sufficient blood product supply is critical and challenging in certain countries and regions, including China. The blood supply in low-income and middle-income countries is insufficient (Kralievits et al., 2015) . The United States has conducted a series of national blood collection and utilization surveys (NBCUSs) (https://www.hhs.gov/ohaidp/initiatives/ blood-tissue-safety/initiatives/national-blood-collection-andutilization-survey/index.html.). Those surveys have provided statistics on the collection and transfusion of blood, have identified trends and have promoted the development and improvement of blood transfusion in the United States. In this study, we have provided statistics on the blood supply in China during 2012-2014 and identified trends. To our knowledge, this is the first overseas report of the blood supply in China. The amount of blood products supply in China increased gradually from 2012 to 2014. In particular, the increases of apheresis PLTs and cryoprecipitate were much higher than those of the other blood components. We also analysed the rates of blood supply according to the Chinese population during 2012-2014 and found that the trends of changes in the rates of blood supply were similar to the changes in the amount of blood supply. These results showed a steadily increasing trend of blood supply in China, which may be derived by a national policy such as the New Rural Cooperative Medical Scheme (NCMS) or by improvements in medical diagnosis and treatment.
A recent report reveals that the transfusion rates in the United States have declined continuously since 2008, but still achieved 35·3 units of RBCs per 1000 population (approximately 88·3 equivalent units in China; 1 unit of WB and RBCs in the United States is equal to 2·5 units in China in volume) in 2015 (Ellingson et al., 2017) , far more than the 14·4 units in China in 2014. The transfusion rates in Europe in 2014 varied between countries, from 12·3 to 51·4 per 1000 population (median: 36·1), but were generally higher than those in China (Janssen & Rautmann, 2017) . The blood transfusion rates are highly influenced by the age structure of the population. In UK, transfusion requirements increase progressively after age 50 (Tinegate et al., 2016) . China's population is ageing, and the percentage of the population aged 65 and over reached 10·5% in 2015 (population data obtained from the National Bureau of Statistics of China http://data.stats.gov.cn/easyquery.htm?cn=C01&zb=A0306& sj=2015); nevertheless, the age structure of the population in China cannot explain the differences in transfusion rates between China and the United States or Europe. The body weights of Chinese adults (60·56 kg) are generally much lower than those of Europeans (75·80 kg, represented by the UK) and Americans (81·93 kg), which may be one of the reasons for the difference between transfusion rates (the body weight data obtained from http://www.telegraph.co.uk/news/earth/ earthnews/9345086/The-worlds-fattest-countries-how-doyou-compare.html). In addition, we believe that the economy and medical diagnosis and treatment are important factors The map is cited from a paper by Chen et al. (2016) . affecting blood transfusion rates. Along with the development of the economy and the improvement of medical diagnosis and treatment in China, the blood supply will continue to grow in the future. Indeed, in recent years, the blood supply could not meet the demand of clinical utilization in many cities of China, namely, 'the blood shortage'. To ensure a sufficient blood supply that can meet the increasing clinical requirements for blood, blood centre management improvement is urgently needed in China. Many methods should be considered, such as strengthening the intensity of propaganda for blood donation recruitment and government-led support in policy making and financing. Moreover, improving clinical blood utilization and strengthening patient blood management will also help counteract the shortage of blood supply (Shi et al., 2014a,b) . In China, the conservative criteria of donor selection, the relatively long donation interval, and the small donation volume have further limited the blood supply; therefore, revising the donation volume, donation interval and age limit for donation should be considered (Shi et al., 2014a,b) . To improve the shortage of supply of apheresis PLTs, the preparation of more WB-derived PLT concentrates should be considered.
We found that the percentages and amount of WB in the WB and RBC supply were low and decreased gradually. This revealed that blood component transfusion had been widely emphasized in clinical practice. Our survey showed that the percentages and amount of RBCs in additive solution, frozen plasma and WB-derived PLT concentrates decreased gradually, whereas the percentages and amount of leukocyte-reduced RBCs in additive solution, fresh-frozen plasma, methylene blue-treated and removed frozen plasma and apheresis PLTs increased. In Iran, the WB blood supply declined, while that of fresh-frozen plasma increased, during 2008-2012, which is consistent with our report (Omidkhoda et al., 2016) . Compared with RBCs in additive solution, leukocyte-reduced RBCs in additive solution can minimize the risk of transmission of viruses such as cytomegalovirus and reduce febrile non-haemolytic transfusion reactions (Wallace et al., 1998; Sullivan et al., 2002) . Methylene blue-treated and removed frozen plasma can minimize the risk of viral transmission compared with frozen plasma, and apheresis PLTs can minimize the risk of human leukocyte antigen (HLA) alloimmunization and viral transmission, compared with WB-derived PLT concentrates. In addition, the changes in the percentages and amount of blood supply were also associated with the improvement of techniques to prepare blood components at the blood centres.
According to the geographic regional population in China, we analysed the rate of blood supply. Large differences between regions were presented, such as the rates of WB and RBC supply; PLTs in North China were highest, while the rate of cryoprecipitate supply ranked highest in South China. The differences may be due to the clinical blood utilization, patient blood management and medical and surgical procedures in the different geographic regions.
It should be noted that the blood supply data from Hong Kong, Macao and Taiwan were not included in this survey.
In summary, we report data regarding the blood supply in China during 2012-2014. Our survey revealed a steadily increasing blood supply trend in China, which indicated improvements of the blood centre system in China. However, in China, there still is a marked shortage of blood supply, and Chinese blood centres continue to face challenges regarding their ability to provide a sufficient blood supply in the future.
